Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.

JonesTrading analyst Soumit Roy maintained a Buy rating on Beam Therapeutics today and set a price target of $35.00. According to TipRanks, Roy is ...

JonesTrading Sticks to Its Buy Rating for Beam Therapeutics (BEAM)

Wedbush analyst David Nierengarten maintained a Buy rating on Beam Therapeutics on March 26 and set a price target of $65.00. The company’s shares ...

Beam Therapeutics (BEAM) Gets a Buy from Wedbush

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), KalVista Pharmaceuticals (...

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ionis Pharmaceuticals (IONS) and Beam Therapeutics (...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stoke Therapeutics (STOK), Embecta Corporation (EMBC...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM – Research Report), Pelthos ...

Market Cap	$2.66B	P/E Ratio	N/A
52W High	$36.44	52W Low	$13.53
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	7.4%	52W Position	55.9%
Overall Score	46	Value Score	60
Quality Score	42	Technical Score	36

EPS Current Est	$-3.9	EPS Next Est	$-3.9
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BEAM	$26.33	0.00%	2.01M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BEAM	$26.33	0%	2.01M
3
4
5
6

BEAM

BEAM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Beam Therapeutics Inc. Data in Excel

Get Beam Therapeutics Inc. Data in Excel